Intellia Therapeutics
Latest round
- Series B
Last raised
- Sep 2015
Total raised
- $85M
Investors
- 8
About Intellia Therapeutics
Intellia Therapeutics, Inc.Intellia Therapeutics, Inc. is engaged in the development of CRISPR gene editing therapies. The company was founded in 2014 and is headquartered in Cambridge, US. The founders are Erik Sontheimer and Rodolphe Barrangou, with Nessan Bermingham serving as CEO.Intellia Therapeutics specializes in developing innovative genome editing treatments aimed at addressing severe diseases through its core product offerings, which include Lonvoguran Ziclumeran (lonvo-z) for patients with Hereditary Angioedema (HAE). These treatments leverage CRISPR technology to create potentially curative solutions, focusing on enhancing patient outcomes by targeting the root causes of genetic disorders. The company's offerings are designed to empower patients by providing confidence in their treatment options, enabling them to make informed decisions regarding their health.Intellia Therapeutics generates revenue through various structured transactions that align with its focus on developing and commercializing its genetic therapies.80 mn. Revenue streams may include partnerships with healthcare institutions for clinical trials and collaborations with pharmaceutical companies on drug development, particularly involving flagship products like Lonvoguran Ziclumeran. These partnerships typically involve agreements that facilitate access to their proprietary research and development capabilities while allowing clients, such as healthcare providers and research organizations, to utilize their innovative therapies. The company is focusing on expanding its offerings for Lonvoguran Ziclumeran and aims to introduce new products targeting other genetic disorders in the coming years. Furthermore, Intellia is exploring opportunities to enter new geographic markets, particularly targeting Europe and Asia by 2025, to broaden its reach and impact.
Who invested in Intellia Therapeutics
8 investors across 2 rounds
See all investors in Intellia Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Intellia Therapeutics
Who invested in Intellia Therapeutics?
Intellia Therapeutics has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Intellia Therapeutics raised?
Intellia Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Intellia Therapeutics last raise money?
Intellia Therapeutics's most recent round on record is a Series B, in Sep 2015.
What does Intellia Therapeutics do?
Intellia Therapeutics is a biotechnology company.
Where is Intellia Therapeutics headquartered?
Intellia Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Intellia Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Intellia Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Intellia Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.